nmdp logo

Hodgkin lymphoma (HL)

Transplant advances and outcomes

Approximately 8,500 individuals are diagnosed with Hodgkin lymphoma (HL) each year in the United States. HL is most frequently diagnosed among people aged 20-34 years. [1] Hematopoietic cell transplantation (HCT), often autologous but occasionally allogeneic, is a treatment option for recurrent disease. Allogeneic HCT outcomes in patients with relapsed/refractory HL have significantly improved over time. [2, 3]

Recommended timing for transplant consultation

  • Primary refractory disease
  • First or subsequent relapse
  • Brentuximab vedotin and check point inhibitor refractory and/or intolerant disease (for alloHCT)

References

  1. National Comprehensive Cancer Network. Hodgkin Lymphoma. (Version 2.2023). Access
  2. Hegerova L, Cao Q, Lazaryan A, et al. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant. 2017; 52(5): 697-703. Access
  3. NMDP and ASTCT Recommended Timing for Transplant Consultation. Download PDF